Evidence map›Paper›PMID 27514027›Full record

ReviewOral diseases2017

Epigenetic gene regulation by histone demethylases: emerging role in oncogenesis and inflammation.

M K Kang, S Mehrazarin, N-H Park, C-Y Wang

Open access · bronzeAbstract readReview
In one paragraph

Review in Oral diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 59 citations in OpenAlex.

  1. Article
  2. Epidrugs in cancer: mechanisms, applications, and future direction.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

M K KangShapiro Laboratory of Viral Oncology and Aging Research, Los Angeles, CA, USA.
S MehrazarinShapiro Laboratory of Viral Oncology and Aging Research, Los Angeles, CA, USA.
N-H ParkShapiro Laboratory of Viral Oncology and Aging Research, Los Angeles, CA, USA.
C-Y WangLaboratory of Molecular Signaling, UCLA School of Dentistry, Los Angeles, CA, USA.
University of California, Los Angeles · US

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
Epigenetic Control of HPV-associated Oral CarcinogenesisR01DE023874 · NIDCR · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KIM, REUBEN HAN-KYU, WANG, CUN-YU · 2013 to 2017
$2.3M
Molecular Control of MSC differentiation and Bone Formation by KDM4BR01AR063089 · NIAMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WANG, CUN-YU · 2013 to 2017
$1.6M
NCI NIH HHS P30 CA016042NIAMS NIH HHS R01 AR063089NIDCR NIH HHS R01 DE023874
6 · The paper itself

Abstract

Histone N-terminal tails of nucleosomes are the sites of complex regulation of gene expression through post-translational modifications. Among these modifications, histone methylation had long been associated with permanent gene inactivation until the discovery of Lys-specific demethylase (LSD1), which is responsible for dynamic gene regulation. There are more than 30 members of the Lys demethylase (KDM) family, and with exception of LSD1 and LSD2, all other KDMs possess the Jumonji C (JmjC) domain exhibiting demethylase activity and require unique cofactors, for example, Fe(II) and α-ketoglutarate. These cofactors have been targeted when devising KDM inhibitors, which may yield therapeutic benefit. KDMs and their counterpart Lys methyltransferases (KMTs) regulate multiple biological processes, including oncogenesis and inflammation. KDMs' functional interactions with retinoblastoma (Rb) and E2 factor (E2F) target promoters illustrate their regulatory role in cell cycle progression and oncogenesis. Recent findings also demonstrate the control of inflammation and immune functions by KDMs, such as KDM6B that regulates the pro-inflammatory gene expression and CD4

Indexed as

Epigenesis, GeneticAlveolar ProcessCarcinogenesisCell CycleChronic PeriodontitisDNA MethylationHistone DemethylasesHumansToothHistone Demethylasesepigeneticshistone lysine methylationoncogenesisoral inflammation

Identifiers

PMID27514027
PMCPMC5493521
OpenAlexW2509053135

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.